跳至主要内容
临床试验/NCT02839278
NCT02839278已完成不适用

Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases

Centre Hospitalier Universitaire de Besancon1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2015年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
150
试验地点
1
主要终点
Expression of costimulatory molecules CD86, CD80, CD40 and class II (HLA-DR) on monocytes

研究概览

简要总结

The aim of the study is to investigate in vitro the impact of a novel anti-inflammatory treatment on costimulatory molecules expressed on monocytes.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Immune-mediated inflammatory disease (non-ST segment elevation myocardial infarction, Rheumatoid arthritis, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Crohn's disease, Ulcerative colitis, Cystic fibrosis, Psoriasis, Multiple sclerosis or major depressive episode)
  • Patient able to understand the reason of the study
  • Patient not opposed to the conservation of biological samples for scientific research

排除标准

  • Pregnant woman
  • Subject without health insurance

研究组 & 干预措施

Immune-mediated inflammatory disease

Experimental

Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).

干预措施: Blood sample (Biological)

结局指标

主要结局

Expression of costimulatory molecules CD86, CD80, CD40 and class II (HLA-DR) on monocytes

时间窗: 24 months

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验